ClinicalTrials.gg
CompletedNCT02320396Updated May 17, 2024Results posted

Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)

A Phase 3 interventional study of Desloratadine 5 mg and Placebo in Seasonal Allergic Rhinitis, sponsored by Organon and Co. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. desloratadine · Rhinitis, Allergic, Seasonal.

Enrollment
4th of 10
449 · median 272
Started
2015
the only one that year
Phase 3
2 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
10 of 10
Organon and Co

Among the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 3, and was the 10th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About desloratadine

desloratadine: first FDA approval 2001 (CLARINEX), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

This is an efficacy and safety study of desloratadine (MK-4117) in Japanese participants with seasonal allergic rhinitis (SAR). The primary hypothesis of this study is that the change from Baseline in Total Nasal Symptom Score (TNSS) is improved by desloratadine compared to placebo.

Read the detailed description

This study consists of a one-week Symptom Confirmation Period during which participants undergo a single-blinded placebo run-in, a two-week double-blind Treatment Period and a two-week Follow-up Period.

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has at least a 2-year history of seasonal allergic rhinitis with typical symptoms
  • Male or female who is unlikely to conceive: a surgically sterilized female, female who has reached natural menopause, or is of and agrees to either remain abstinent or use (or have her partner use) 2 acceptable methods of from study start through 14 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Has a lower respiratory tract infection or has a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment
  • Has a coexisting infection or systemic mycosis for which there are no effective antibiotics
  • Has asthma that is under treatment and/or uncontrolled
  • Has nasal septum ulcers, nasal surgery, or nasal trauma which have not healed
  • Has vasomotor rhinitis or eosinophilic rhinitis
  • Has a history of to antihistamines or ingredients of study drug
  • Has had treatment with (oral, injectable, suppository, depot drugs [injectable]) or immunological drugs within 28 days prior to Visit 2
  • Is currently receiving treatment with another drug or has received an investigational drug within prior 3 months
  • Has started specific desensitization therapy (allergen immunotherapy) or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who has received such therapies within prior 3 months
  • Has received coagulation or resection using laser therapy etc. for treatment for nasal symptoms
  • Will receive nasal nebulizer therapy and/or thermotherapy during study period
  • Has severe hepatic, renal, cardiac, hematological disease, or other serious coexisting diseases and whose general condition is poor
  • Has a history of or hematological disorder, except for adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix
  • Has a history of severe drug allergy (e.g. anaphylactoid reaction)
  • Is pregnant or lactating or may be pregnant
  • Is planning a remote trip for more than 1 day during the Symptom Confirmation Period or for more than 2 days during the Treatment Period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
449 participants (actual)

Study arms

  • Experimental
    Desloratadine

    After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.

    Drug: Desloratadine 5 mg

  • Placebo comparator
    Placebo

    After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy

    The TNSS was used to evaluate participant nasal symptoms of: sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose) as rated in the participant's diary. The TNSS was the sum of the 4 nasal symptom sub-scores. TNSS scores ranged from 0 to 16, with a higher score indicating more frequent/severe nasal symptoms. Baseline (BL) measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement was an average from Day 1 to Day 13 (2 week average). Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 1 to Day 13 (Weeks 1 through 2 average) of double-blind treatment

  2. Number of Participants Who Experience at Least One Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE.

    Time frame: Up to 4 weeks (Up to 2 weeks after last dose of study drug)

  3. Number of Participants Who Discontinue Study Drug Due to an AE

    An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE.

    Time frame: Up to 2 weeks

Secondary outcomes

  1. Change From Baseline in TNSS for Week 1 and Week 2 of Double-blind Treatment

    The TNSS was used to evaluate participant nasal symptoms of: sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose) as rated in the participant's diary. The TNSS was the sum of the 4 nasal symptom sub-scores. TNSS scores ranged from 0 to 16, with a higher score indicating more frequent/severe nasal symptoms. Baseline (BL) measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement for Week 1 was an average from Day 1 to Day 7 and post-BL measurement for Week 2 was an average from Day 8 to Day 13. Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 1 to 7 (Week 1 average), Day 8 to 13 (Week 2 average) of double-blind treatment

  2. Change From Baseline to Week 1 in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching)

    Nasal symptoms sub-scores rated in the participant's diary included sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores ranged from 0 to 4, with a higher score indicating more frequent/severe nasal symptoms. BL measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement for Week 1 was an average of scores from Day 1 to Day 7. Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 1 to 7 (Week 1 average) of double-blind treatment

  3. Change From Baseline to Week 2 in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching)

    Nasal symptoms sub-scores rated in the participant's diary included sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores ranged from 0 to 4, with a higher score indicating more frequent/severe nasal symptoms. BL measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement for Week 2 was an average of scores from Day 8 to Day 13. Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 8 to 13 (Week 2 average) of double-blind treatment

  4. Change From Baseline in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching) During 2 Weeks of Therapy

    Nasal symptoms sub-scores rated in the participant's diary included sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores ranged from 0 to 4, with a higher score indicating more frequent/severe nasal symptoms. BL measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement for 2 week Average was an average of scores from Day 1 to Day 13. Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 1 to Day 13 (Weeks 1 through 2 average)

  5. Change From Baseline to Week 1 in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes)

    Eye symptoms rated in the participant's diary included eye pruritis (eye itching scored from 0 \[none\] to 4 \[severe eye itching, requiring frequent rubbing of eye\]) and watering eyes (scored from 0 \[none\] to 4 \[severe eye watering requiring frequent wiping of eyes\]). Eye symptom scores ranged from 0 to 4, with a higher score indicating greater severity of symptom. The change from baseline in eye pruritis, eye watering, and the worse one of either eye symptom were reported. Baseline measurement was an average of scores for 3 days prior to treatment. Post-baseline measurement for Week 1 was an average of scores from Day 1 to Day 7. Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 1 to 7 (Week 1 average) of double-blind treatment

  6. Change From Baseline to Week 2 in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes)

    Eye symptoms rated in the participant's diary included eye pruritis (eye itching scored from 0 \[none\] to 4 \[severe eye itching, requiring frequent rubbing of eye\]) and watering eyes (scored from 0 \[none\] to 4 \[severe eye watering requiring frequent wiping of eyes\]). Eye symptom scores ranged from 0 to 4, with a higher score indicating greater severity of symptom. The change from baseline in eye pruritis, eye watering, and the worse one of either eye symptom were reported. Baseline measurement was an average of scores for 3 days prior to treatment. Post-BL measurement for Week 2 was an average of scores from Day 8 to Day 13. Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 8 to 13 (Week 2) of double-blind treatment

  7. Change From Baseline in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes) During 2 Weeks of Therapy

    Eye symptoms rated in the participant's diary included eye pruritis (eye itching scored from 0 \[none\] to 4 \[severe eye itching, requiring frequent rubbing of eye\]) and watering eyes (scored from 0 \[none\] to 4 \[severe eye watering requiring frequent wiping of eyes\]). Eye symptom scores ranged from 0 to 4, with a higher score indicating greater severity of symptom. The change from baseline in eye pruritis, eye watering, and the worse one of either eye symptom were reported. BL measurement was an average of scores for 3 days prior to treatment. Post-BL measurement for 2 week Average was an average of scores from Day 1 to Day 13. Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 1 to Day 13 (Weeks 1 through 2 average)

  8. Change From Baseline in Interference With Daily Activities Score at Week 1, Week 2, and During 2 Weeks of Therapy

    Interference of allergic rhinitis symptoms with overall daily activities (such as work, study, housekeeping, sleep, or outing) was rated by the participant according to the following scale: 0=none, 1= symptoms cause few troubles, 2=symptoms cause intermediate problems between 1 and 3, 3=nasal symptoms cause painful and complicating daily life, or 4 = symptoms make daily activities impossible. Interference with daily activities scores ranged from 0 to 4 maximum, with a higher score indicating greater interference with daily activities. Baseline measurement was an average of scores for 3 days prior to treatment. Post-baseline measurement for Week 1 was an average of scores from Day 1 to Day 7. Post-BL measurement for Week 2 was an average of scores from Day 8 to Day 13. Post-BL measurement for 2 week Average was an average of scores from Day 1 to Day 13. Change from BL = Post BL measurement - BL measurement.

    Time frame: Baseline, Day 1 to 7 (Week 1 average), Day 8 to 13 (Week 2 average), Day 1 to Day 13 (Weeks 1 through 2 average) of double-blind treatment

  9. Percentage of Participants With Impression Assessments of "Better" or "Much Better" as Assessed by the Investigator at Week 2

    The investigator assessed the participant's symptoms of allergic rhinitis and nasal findings at the end of the study (2 week visit or discontinuation visit) compared with those at the start of the study period (based on their recollection/memory of the participant's symptoms, no formal baseline assessment) and evaluated their impression of study drug on effect according to 6 grades: Much better, Better, Slightly better, Unchanged, Worse, or Unevaluable. The evaluation result and reason for judgment (if needed) was recorded in the participant's case report form. The investigator's impression was evaluated based on the symptoms for allergic rhinitis, nasal findings and participant's own impression at Week 2. The percentage of participants with assessments of "Better" and "Much better" graded by the investigator (Investigator's Impression Rate) was reported and analyzed using Odds Ratio analysis.

    Time frame: From Baseline to Week 2

  10. Percentage of Participants With Impression Assessments of "Better" or "Much Better" as Assessed Participants at Week 2

    The participant evaluated their symptoms of allergic rhinitis at the end of the study (2 week visit or discontinuation visit) compared with those at the start of the study period (based on their recollection/memory of their symptoms, no formal baseline assessment) and recorded in their Subject Allergy Diary their impression of study drug on effect according to 6 grades: Much better, Better, Slightly better, Unchanged, Worse, or Unevaluable. The percentage of participants with assessments of "Better" and "Much better" graded by the participant (Participant's Impression Rate) was reported and analyzed using Odds Ratio analysis.

    Time frame: From Baseline to Week 2

07

Results

Posted May 30, 2016

Participant flow

Participants with seasonal allergic rhinitis (SAR) were recruited at 3 study sites in Japan.

Participant flow — Overall Study
MilestoneDesloratadinePlacebo
Started224225
Treated (full analysis set)223225
Completed220221
Not completed44
Withdrew: Adverse event22
Withdrew: Pregnancy01
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryChange From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy

The TNSS was used to evaluate participant nasal symptoms of: sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose) as rated in the participant's diary. The TNSS was the sum of the 4 nasal symptom sub-scores. TNSS scores ranged from 0 to 16, with a higher score indicating more frequent/severe nasal symptoms. Baseline (BL) measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement was an average from Day 1 to Day 13 (2 week average). Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 1 to Day 13 (Weeks 1 through 2 average) of double-blind treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy
units on a scaleDesloratadinePlacebo
Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy-1.41 (-1.64 to -1.19)-0.59 (-0.81 to -0.36)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in least squares (ls) means: -0.83 · 95% CI -1.14 to -0.51
PrimaryNumber of Participants Who Experience at Least One Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE.

Time frame:
Up to 4 weeks (Up to 2 weeks after last dose of study drug)
Reported as:
Number · participants
Number of Participants Who Experience at Least One Adverse Event (AE)
participantsDesloratadinePlacebo
Number of Participants Who Experience at Least One Adverse Event (AE)1913
PrimaryNumber of Participants Who Discontinue Study Drug Due to an AE

An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE.

Time frame:
Up to 2 weeks
Reported as:
Number · participants
Number of Participants Who Discontinue Study Drug Due to an AE
participantsDesloratadinePlacebo
Number of Participants Who Discontinue Study Drug Due to an AE22
SecondaryChange From Baseline in TNSS for Week 1 and Week 2 of Double-blind Treatment

The TNSS was used to evaluate participant nasal symptoms of: sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose) as rated in the participant's diary. The TNSS was the sum of the 4 nasal symptom sub-scores. TNSS scores ranged from 0 to 16, with a higher score indicating more frequent/severe nasal symptoms. Baseline (BL) measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement for Week 1 was an average from Day 1 to Day 7 and post-BL measurement for Week 2 was an average from Day 8 to Day 13. Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 1 to 7 (Week 1 average), Day 8 to 13 (Week 2 average) of double-blind treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline in TNSS for Week 1 and Week 2 of Double-blind Treatment
units on a scaleDesloratadinePlacebo
Week 1-1.19 (-1.42 to -0.96)-0.38 (-0.61 to -0.15)
Week 2-1.69 (-1.96 to -1.41)-0.84 (-1.12 to -0.57)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.82 · 95% CI -1.14 to -0.50
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.84 · 95% CI -1.23 to -0.46
SecondaryChange From Baseline to Week 1 in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching)

Nasal symptoms sub-scores rated in the participant's diary included sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores ranged from 0 to 4, with a higher score indicating more frequent/severe nasal symptoms. BL measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement for Week 1 was an average of scores from Day 1 to Day 7. Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 1 to 7 (Week 1 average) of double-blind treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 1 in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching)
units on a scaleDesloratadinePlacebo
Sneezing-0.39 (-0.47 to -0.31)-0.14 (-0.22 to -0.06)
Rhinorrhea-0.34 (-0.42 to -0.26)-0.13 (-0.21 to -0.05)
Nasal Congestion-0.02 (-0.07 to 0.03)0.07 (0.03 to 0.12)
Nasal Itching-0.45 (-0.53 to -0.36)-0.18 (-0.26 to -0.09)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.35 to -0.14
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.21 · 95% CI -0.32 to -0.10
  • Desloratadine vs Placebo · cLDA model · p = 0.008 · Difference in ls means: -0.09 · 95% CI -0.16 to -0.02
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.27 · 95% CI -0.38 to -0.15
SecondaryChange From Baseline to Week 2 in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching)

Nasal symptoms sub-scores rated in the participant's diary included sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores ranged from 0 to 4, with a higher score indicating more frequent/severe nasal symptoms. BL measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement for Week 2 was an average of scores from Day 8 to Day 13. Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 8 to 13 (Week 2 average) of double-blind treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 2 in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching)
units on a scaleDesloratadinePlacebo
Sneezing-0.51 (-0.60 to -0.42)-0.27 (-0.35 to -0.18)
Rhinorrhea-0.49 (-0.58 to -0.40)-0.24 (-0.33 to -0.16)
Nasal Congestion-0.03 (-0.09 to 0.03)0.06 (-0.00 to 0.12)
Nasal Itching-0.65 (-0.75 to -0.55)-0.39 (-0.49 to -0.29)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.36 to -0.13
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.37 to -0.12
  • Desloratadine vs Placebo · cLDA model · p = 0.037 · Difference in ls means: -0.09 · 95% CI -0.18 to -0.01
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.26 · 95% CI -0.40 to -0.12
SecondaryChange From Baseline in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching) During 2 Weeks of Therapy

Nasal symptoms sub-scores rated in the participant's diary included sneezing (daily frequency of attacks scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), rhinorrhea (daily frequency of blowing nose scored from 0 \[\<1 time or "none"\] to 4 \[≥21 times\]), nasal congestion (scored from 0 \[no nasal blockage\] to 4 \[completely obstructed all day\]), and nasal itching (scored from 0 \[none\] to 4 \[nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores ranged from 0 to 4, with a higher score indicating more frequent/severe nasal symptoms. BL measurement was an average of scores for 3 days prior to treatment (during Confirmation of Symptom Period). Post-BL measurement for 2 week Average was an average of scores from Day 1 to Day 13. Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 1 to Day 13 (Weeks 1 through 2 average)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Each Nasal Symptom Sub-Score (Sneezing, Rhinorrhea, Nasal Congestion and Nasal Itching) During 2 Weeks of Therapy
units on a scaleDesloratadinePlacebo
Sneezing-0.44 (-0.52 to -0.37)-0.20 (-0.27 to -0.12)
Rhinorrhea-0.41 (-0.48 to -0.33)-0.18 (-0.26 to -0.11)
Nasal Congestion-0.02 (-0.07 to 0.03)0.07 (0.02 to 0.12)
Nasal Itching-0.54 (-0.62 to -0.46)-0.27 (-0.36 to -0.19)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.35 to -0.14
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.23 · 95% CI -0.33 to -0.12
  • Desloratadine vs Placebo · cLDA model · p = 0.009 · Difference in ls means: -0.09 · 95% CI -0.16 to -0.02
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.26 · 95% CI -0.38 to -0.15
SecondaryChange From Baseline to Week 1 in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes)

Eye symptoms rated in the participant's diary included eye pruritis (eye itching scored from 0 \[none\] to 4 \[severe eye itching, requiring frequent rubbing of eye\]) and watering eyes (scored from 0 \[none\] to 4 \[severe eye watering requiring frequent wiping of eyes\]). Eye symptom scores ranged from 0 to 4, with a higher score indicating greater severity of symptom. The change from baseline in eye pruritis, eye watering, and the worse one of either eye symptom were reported. Baseline measurement was an average of scores for 3 days prior to treatment. Post-baseline measurement for Week 1 was an average of scores from Day 1 to Day 7. Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 1 to 7 (Week 1 average) of double-blind treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 1 in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes)
units on a scaleDesloratadinePlacebo
Eye Pruritus-0.34 (-0.41 to -0.26)-0.09 (-0.17 to -0.01)
Watering Eyes-0.17 (-0.24 to -0.11)-0.02 (-0.08 to 0.05)
Worse of Pruritus or Watering Eyes-0.34 (-0.42 to -0.27)-0.09 (-0.17 to -0.01)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.35 to -0.15
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.16 · 95% CI -0.24 to -0.08
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.35 to -0.15
SecondaryChange From Baseline to Week 2 in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes)

Eye symptoms rated in the participant's diary included eye pruritis (eye itching scored from 0 \[none\] to 4 \[severe eye itching, requiring frequent rubbing of eye\]) and watering eyes (scored from 0 \[none\] to 4 \[severe eye watering requiring frequent wiping of eyes\]). Eye symptom scores ranged from 0 to 4, with a higher score indicating greater severity of symptom. The change from baseline in eye pruritis, eye watering, and the worse one of either eye symptom were reported. Baseline measurement was an average of scores for 3 days prior to treatment. Post-BL measurement for Week 2 was an average of scores from Day 8 to Day 13. Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 8 to 13 (Week 2) of double-blind treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 2 in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes)
units on a scaleDesloratadinePlacebo
Eye Pruritus-0.56 (-0.66 to -0.46)-0.32 (-0.41 to -0.22)
Watering Eyes-0.26 (-0.34 to -0.18)-0.13 (-0.20 to -0.05)
Worse of Pruritus or Watering Eyes-0.56 (-0.66 to -0.46)-0.32 (-0.41 to -0.22)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.37 to -0.12
  • Desloratadine vs Placebo · cLDA model · p = 0.010 · Difference in ls means: -0.13 · 95% CI -0.24 to -0.03
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.24 · 95% CI -0.37 to -0.12
SecondaryChange From Baseline in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes) During 2 Weeks of Therapy

Eye symptoms rated in the participant's diary included eye pruritis (eye itching scored from 0 \[none\] to 4 \[severe eye itching, requiring frequent rubbing of eye\]) and watering eyes (scored from 0 \[none\] to 4 \[severe eye watering requiring frequent wiping of eyes\]). Eye symptom scores ranged from 0 to 4, with a higher score indicating greater severity of symptom. The change from baseline in eye pruritis, eye watering, and the worse one of either eye symptom were reported. BL measurement was an average of scores for 3 days prior to treatment. Post-BL measurement for 2 week Average was an average of scores from Day 1 to Day 13. Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 1 to Day 13 (Weeks 1 through 2 average)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Eye Symptoms (Pruritus, Watering Eyes and the Worse One of Either Pruritus or Watering Eyes) During 2 Weeks of Therapy
units on a scaleDesloratadinePlacebo
Eye Pruritus-0.44 (-0.52 to -0.36)-0.19 (-0.27 to -0.12)
Watering Eyes-0.21 (-0.27 to -0.15)-0.07 (-0.13 to -0.00)
Worse of Pruritus or Watering Eyes-0.44 (-0.52 to -0.36)-0.19 (-0.27 to -0.12)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.35 to -0.14
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.15 · 95% CI -0.23 to -0.07
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.25 · 95% CI -0.35 to -0.15
SecondaryChange From Baseline in Interference With Daily Activities Score at Week 1, Week 2, and During 2 Weeks of Therapy

Interference of allergic rhinitis symptoms with overall daily activities (such as work, study, housekeeping, sleep, or outing) was rated by the participant according to the following scale: 0=none, 1= symptoms cause few troubles, 2=symptoms cause intermediate problems between 1 and 3, 3=nasal symptoms cause painful and complicating daily life, or 4 = symptoms make daily activities impossible. Interference with daily activities scores ranged from 0 to 4 maximum, with a higher score indicating greater interference with daily activities. Baseline measurement was an average of scores for 3 days prior to treatment. Post-baseline measurement for Week 1 was an average of scores from Day 1 to Day 7. Post-BL measurement for Week 2 was an average of scores from Day 8 to Day 13. Post-BL measurement for 2 week Average was an average of scores from Day 1 to Day 13. Change from BL = Post BL measurement - BL measurement.

Time frame:
Baseline, Day 1 to 7 (Week 1 average), Day 8 to 13 (Week 2 average), Day 1 to Day 13 (Weeks 1 through 2 average) of double-blind treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline in Interference With Daily Activities Score at Week 1, Week 2, and During 2 Weeks of Therapy
units on a scaleDesloratadinePlacebo
Week 1-0.23 (-0.29 to -0.16)-0.07 (-0.14 to -0.01)
Week 2-0.34 (-0.42 to -0.26)-0.14 (-0.22 to -0.06)
2 Week Average-0.28 (-0.34 to -0.21)-0.10 (-0.17 to -0.04)
Statistical analysis
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.16 · 95% CI -0.24 to -0.07
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.19 · 95% CI -0.30 to -0.09
  • Desloratadine vs Placebo · cLDA model · p = <0.001 · Difference in ls means: -0.17 · 95% CI -0.26 to -0.08
SecondaryPercentage of Participants With Impression Assessments of "Better" or "Much Better" as Assessed by the Investigator at Week 2

The investigator assessed the participant's symptoms of allergic rhinitis and nasal findings at the end of the study (2 week visit or discontinuation visit) compared with those at the start of the study period (based on their recollection/memory of the participant's symptoms, no formal baseline assessment) and evaluated their impression of study drug on effect according to 6 grades: Much better, Better, Slightly better, Unchanged, Worse, or Unevaluable. The evaluation result and reason for judgment (if needed) was recorded in the participant's case report form. The investigator's impression was evaluated based on the symptoms for allergic rhinitis, nasal findings and participant's own impression at Week 2. The percentage of participants with assessments of "Better" and "Much better" graded by the investigator (Investigator's Impression Rate) was reported and analyzed using Odds Ratio analysis.

Time frame:
From Baseline to Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With Impression Assessments of "Better" or "Much Better" as Assessed by the Investigator at Week 2
percentage of participantsDesloratadinePlacebo
Much better2.33.1
Better26.117.9
Better + Much better Total28.421.0
Less than better Total71.679.0
Statistical analysis
  • Desloratadine vs Placebo · Regression, Logistic · p = 0.071 · Odds ratio (or): 1.492 · 95% CI 0.966 to 2.303
SecondaryPercentage of Participants With Impression Assessments of "Better" or "Much Better" as Assessed Participants at Week 2

The participant evaluated their symptoms of allergic rhinitis at the end of the study (2 week visit or discontinuation visit) compared with those at the start of the study period (based on their recollection/memory of their symptoms, no formal baseline assessment) and recorded in their Subject Allergy Diary their impression of study drug on effect according to 6 grades: Much better, Better, Slightly better, Unchanged, Worse, or Unevaluable. The percentage of participants with assessments of "Better" and "Much better" graded by the participant (Participant's Impression Rate) was reported and analyzed using Odds Ratio analysis.

Time frame:
From Baseline to Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With Impression Assessments of "Better" or "Much Better" as Assessed Participants at Week 2
percentage of participantsDesloratadinePlacebo
Much better5.94.9
Better30.616.1
Better + Much better Total36.521.1
Less than better Total63.578.9
Statistical analysis
  • Desloratadine vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.149 · 95% CI 1.408 to 3.280

Adverse events

Collected over Up to 4 weeks (Up to 2 weeks after last dose of study drug). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Desloratadine—1/223 (0.4%)0/223 (0%)
Placebo—0/225 (0%)0/225 (0%)
Most frequent serious events
Most frequent serious events
EventDesloratadinePlacebo
Postoperative wound infectionInfections and infestations1/2230/225

Baseline characteristics

All Randomized Participants

Age, Continuous
Age, Continuous(years)DesloratadinePlaceboTotal
Mean40.0 ± 10.939.8 ± 10.939.9 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)DesloratadinePlaceboTotal
Female130131261
Male9494188
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Okubo K, Maeda Y, Oshima N, Hisada S. A Phase III clinical trial of desloratadine in Japanese subjects with seasonal allergic rhinitis: A randomized controlled trial. Arerugi. 2016;32(11):863-876.. [in Japanese] https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=11

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Apr 2015, 3 months.

Results were first posted in May 2016, 1 year 1 month after primary completion.

Of 31 industry-sponsored phase 3 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 3 months is below that.

Counting every sponsor, half of 37 studies reached it within 4 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2014
First posted
Dec 19, 2014
StartActual
Jan 9, 2015
Primary completionActual
Apr 27, 2015
CompletionActual
Apr 27, 2015
Results first posted
May 30, 2016
Last update
May 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02320396
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Dec 19, 2014
Start date
Jan 9, 2015
Primary completion
Apr 27, 2015
Completion
Apr 27, 2015
Results posted
May 30, 2016
Last update
May 17, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion